ArticleACS applied bio materials2026
Dual pH-Responsive Calcium Phosphate Nanoparticles Conjugated with Folate by CuAAC Click Chemistry for Targeted Gemcitabine Delivery to Cancer Cells.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calcium Phosphate Nanostructured Biocomposites with Applications in Bone Tissue Engineering.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium phosphate nanoparticles (CaP NPs) are biocompatible carriers widely studied for drug delivery due to their pH-responsive degradation and controlled release properties. In this study, CaP NPs stabilized with carboxymethyl cellulose (CMC) and coated with a silica layer were designed for gemcitabine (GEM) loading and folate (FA) conjugation, targeting cancer cells overexpressing folate receptor alpha (FRα). GEM was covalently coupled to CMC via an amide bond before CaP precipitation, creating a prodrug system. The NPs exhibited dual pH-responsive release, in which CaP dissolution combined with polymer-drug cleavage through acid-catalyzed hydrolysis of CMC-GEM within endolysosomes ensured intracellular bioavailability of free GEM molecules. FA conjugation by strong covalent bonds via copper-catalyzed azide-alkyne cycloaddition (CuAAC) click reaction enhanced the uptake of CaP NPs in FRα-positive breast cancer cells (MCF-7), whereas both FA-conjugated and nonconjugated NPs exhibited similar uptake in normal human mesenchymal stem cells (hMSCs). GEM-loaded CaP NPs showed high cytotoxicity in FRα-overexpressing cancer cell lines (MCF-7, MDA-MB-231, HeLa), while FA conjugation significantly reduced toxicity in hMSCs without compromising anticancer activity. These findings demonstrate the potential of FA-conjugated and GEM-loaded CaP NPs as a nanoplatform for targeted cancer therapy with reduced toxicity in healthy cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.